# Product Introduction

## CI994 (Tacedinaline)

CI-994 (Tacedinaline) is an anti-cancer drug which inhibits **HDAC1** with **IC50** of 0.57 μM and causes G1 cell cycle arrest. Phase 3.

### Technical Data:

| | | |
|---|---|---|
| **Molecular Weight (MW):** | 269.3 |  |
| **Formula:** | $C_{15}H_{15}N_3O_2$ | |
| **Solubility (25°C) * <1 mg/ml means slightly soluble or insoluble:** | DMSO 54 mg/mL | |
| | Water <1 mg/mL | |
| | Ethanol <1 mg/mL | |
| **Purity:** | >98% | |
| **Storage:** | 3 years -20℃Powder | |
| | 6 months-80℃in DMSO | |
| **CAS No.:** | 112522-64-2 | |

### Biological Activity

CI-994 (< 160 mM) shows cytostatic effect with concomitant increase at G0/G1 phase, a reduction at S phase level and increased apoptosis in A-549 and LX-1 cells. [2] CI-994 inhibits growth of LNCaP cell with IC50 of 7.4 μM. [3] CI-994 exerts activity against several tumor cell lines with greater cytotoxicity against the solid tumors relative to both the leukemia and normal fibroblast cell lines. [4] CI-994 inhibits growth of rat leukemia BCLO cells with IC50 of 2.5 μM. [5]

CI-994 exerts demonstrated antitumor activity against several tumor models, including the

chemo-resistant mouse pancreatic ductal carcinoma as well as the human prostate tumor model LNCaP. [4]

## References


[1] Methot JL, et al. Bioorg Med Chem Lett, 2008, 18(3), 973-978.

[2] Loprevite M, et al. A Oncol Res, 2005, 15(1), 39-48.

[3] Gediya LK, et al. Bioorg Med Chem, 2008, 16(6), 3352-3360.

[4] LoRusso PM, et al. Invest New Drugs, 1996, 14(4), 349-356.

[5] Hubeek I, et al. Oncol Rep, 2008, 19(6), 1517-1523.


Note： Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer’s risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.